Associate Professor

Robert Kridel

PhD, University of British Columbia

Publications

Location

Princess Margaret Cancer Research Tower

Address

101 College Street, 12th floor, Rm 12.306, Toronto, Ontario Canada M5G 1L7

Research Interests

Cancer Diagnosis and Therapy, Cancer Mechanisms and Models, Data Science and Computational Biology

At a Glance

Areas of focus include:

lymphoma
translational research
cancer genomics
functional genomics

Short Bio

Dr. Kridel has been a faculty member at the Princess Margaret Cancer Centre since 2017. His research interests include lymphoma genomics and their correlation with treatment response, as well as the discovery of novel therapeutic approaches to improve patient outcomes. He completed his medical training and medical oncology residency in Luxembourg, Belgium and Switzerland, and obtained his PhD from the University of British Columbia.

Research Synopsis

Our research focuses on overcoming treatment resistance in mature lymphoid malignancies through a multi-pronged strategy. One major pillar of our work involves comprehensive multi-omic profiling of tissue and plasma from large patient cohorts to identify novel biomarkers. This work led to the identification of novel genetic and epigenetic subtypes of follicular lymphoma. It established FOXP1 expression as a prognostic biomarker, increasingly recognized as a hallmark of the memory B-cell-like subtype. More recently, we have focused on circulating tumour DNA (ctDNA) as a cost-effective, non-invasive biomarker for risk prediction in large B-cell lymphoma, highlighted by our co-leadership of a ctDNA-adapted clinical trial. In parallel, our group is developing rational combination therapies to overcome resistance to epigenetic agents. This includes the discovery that degradation of Ikaros and Aiolos restores sensitivity to EZH2 inhibitors, as well as the preclinical development of novel targeted protein degraders.

Recent Publications

Risk Assessment with Ultra-Low-Pass Whole Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma. Zhao D, Lang N, ..., Kridel R. JCO Precision Oncology. 2025 Jul;9:e2500200.
Glofitamab with Polatuzumab Vedotin in Refractory Burkitt’s Lymphoma. Prica A, Roschweski M, Beale P, Pittaluga S, Delabie J, Ortega C, Kridel R. N Engl J Med. 2025 May 1;392(17):1760-1762
GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. He MY, ..., Kridel R. Leukemia. 2024 Oct;38(10):2210-2224.
Identification of Genetic Subtypes in Follicular Lymphoma. Shelton V, ..., Kridel R. Blood Cancer Journal. 2024 Aug 7;14(1):128.
In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program. Isaev K, ..., Kridel R. Haematologica. 2023 Jan 1;108(1):196-206.
Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma. Lackraj T,* Ben Barouch S,* Medeiros JJF,* ..., Abelson S,* Kridel R.* American Journal of Hematology. 2022 Dec;97(12):1538-1547.
Combined EZH2 inhibition and Ikaros degradation leads to enhanced anti-tumor activity in diffuse large B-cell lymphoma. Tong KI,* Yoon S,* Isaev K,* ..., Kridel R. Clinical Cancer Research 2021 Oct;27(19):5401-5414. (* denotes equal contribution)
Molecular Attributes Underlying Central Nervous System and Systemic Relapse in Diffuse Large B-cell Lymphoma. Isaev K, ..., Kridel R. Haematologica. 2021 May 1;106(5):1466-1471.
FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab-containing regimens. Mottok A,* Jurinovic V,* … Hoster E,* Weigert O,* Kridel R.* Blood. 2018 Jan 11;131(2):226-235. (* denotes equal contribution)